Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

(2012) Jeffrey L. Wolf et al.   LEUKEMIA & LYMPHOMA

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Clinical development of panobinostat in classical Hodgkin’s lymphoma

(2011) Yasuhiro Oki et al.   Expert Review of Hematology

Relapsed Multiple Myeloma

(2011) S. Lonial   Hematology-American Society of Hematology Education Program

microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia

(2010) A. M. Roccaro et al.   BLOOD

Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology

(2010) Antonio Sacco et al.   Journal of Hematology & Oncology

Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients

(2010) Meghan Rourke et al.   LEUKEMIA & LYMPHOMA

International prognostic scoring system for Waldenstrom macroglobulinemia

(2009) P. Morel et al.   BLOOD

How I treat Waldenstrom macroglobulinemia

(2009) S. P. Treon   BLOOD

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

(2009) Michael Dickinson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

(2009) H Miles Prince et al.   Future Oncology

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

(2009) Steven P. Treon et al.   JOURNAL OF CLINICAL ONCOLOGY

Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia

(2008) Meletios Athanasios Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY